Literature DB >> 6185256

Interferon and natural killer cells in systemic lupus erythematosus.

O Strannegård, S Hermodsson, G Westberg.   

Abstract

Natural killer (NK) cell activity against several types of target cells was found to be subnormal in patients with systemic lupus erythematosus (SLE). Interferon (IFN) boosted the NK activity of cells from SLE patients to a significantly lesser degree than cells from normal controls. The production of IFN after stimulation of blood cells with Sendai virus was significantly decreased in SLE patients with active disease, and in a substantial proportion of the patients the production of phytohaemagglutinin (PHA)-induced IFN was below normal limits. Although the production of virus-induced IFN was clearly inversely correlated to disease activity no such correlation was observed for PHA-induced IFN. Serum levels of both pH2 stable and pH2 labile IFN were significantly higher in SLE patients than in controls. The findings clearly show that SLE is associated with abnormalities in the NK cell-IFN system but it cannot be stated whether these abnormalities are causally related to the development of disease or are secondary to pathological changes in SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6185256      PMCID: PMC1536671     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus.

Authors:  N I Abdou; A Sagawa; E Pascual; J Hebert; S Sadeghee
Journal:  Clin Immunol Immunopathol       Date:  1976-09

2.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

3.  Responses of fractionated cells from patients with systemic lupus erythematosus and normals to plant mitogen: evidence for a suppressor population of monocytes.

Authors:  J A Markenson; J W Morgan; M D Lockshin; C Joachim; J B Winfield
Journal:  Proc Soc Exp Biol Med       Date:  1978-05

4.  Time and dosage dependence of immunoenhancement by murine type II interferon preparations.

Authors:  G Sonnenfeld; A D Mandel; T C Merigan
Journal:  Cell Immunol       Date:  1978-10       Impact factor: 4.868

5.  Interferon production by lymphocytes from patients with systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; J Ruiz-Gómez; E Fishbein; M E Bustamante
Journal:  Arthritis Rheum       Date:  1974 Sep-Oct

6.  Serum factors causing impaired macrophage function in systemic lupus erythematosus.

Authors:  B O Svensson
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

7.  Depression of cellular-mediated immunity in systemic lupus erythematosus. relation to disease activity.

Authors:  C J Rosenthal; E C Franklin
Journal:  Arthritis Rheum       Date:  1975 May-Jun

8.  Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus.

Authors:  R P Messner; F D Lindström; R C Williams
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

9.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  6 in total

1.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

Authors:  H Vallin; S Blomberg; G V Alm; B Cederblad; L Rönnblom
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

3.  Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.

Authors:  N J Struyf; H W Snoeck; C H Bridts; L S De Clerck; W J Stevens
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

4.  Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm; R Manthorpe; V Andersen
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

5.  BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.

Authors:  A Dzionek; Y Sohma; J Nagafune; M Cella; M Colonna; F Facchetti; G Günther; I Johnston; A Lanzavecchia; T Nagasaka; T Okada; W Vermi; G Winkels; T Yamamoto; M Zysk; Y Yamaguchi; J Schmitz
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

6.  17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG.

Authors:  Xiaoxi Li; Yixin Xu; Ling Ma; Lingyun Sun; Gengfeng Fu; Yayi Hou
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.